廣信材料(300537.SZ):子公司擬1460萬元購買東莞中微興品100%股權
格隆匯 3 月 10日丨廣信材料(300537.SZ)公佈,公司之全資子公司江蘇宏泰高分子材料有限公司(“江蘇宏泰”)與自然人梁少瓊於2021年3月10日簽署了《股權轉讓協議》。江蘇宏泰擬以自有資金1460萬元購買自然人梁少瓊持有的東莞中微興品科技有限公司(“東莞中微興品”)100%股權。此次交易完成後,江蘇宏泰將持有東莞中微興品100%的股權。
江蘇宏泰以1460萬元現金方式支付購買東莞中微興品100%股權的事項,目的是為獲得其名下位於東莞市寮步鎮仁居路1號松湖智谷研發中心一區5號丙類廠房2001-2003號房屋的所有權。
此次投資能有效解決華南區域實驗室和業務人員辦公場所受限問題,有利於進一步完善江蘇宏泰的業務拓展、貼近客户服務、增強核心競爭能力和持續經營能力。符合公司戰略發展規劃,有利於江蘇宏泰及母公司的長遠發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.